COPB2: A Novel Prognostic Biomarker That Affects Progression of HCC
Purpose. This study is aimed at investigating the expression, underlying biological function, and clinical significance of coatomer protein complex subunit beta 2 (COPB2) in hepatocellular carcinoma (HCC). Methods. HCC-related data were extracted from The Cancer Genome Atlas (TCGA) database, Interna...
Gespeichert in:
| Veröffentlicht in: | BioMed research international 2021, Vol.2021, p.6648078-14 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 14 |
|---|---|
| container_issue | |
| container_start_page | 6648078 |
| container_title | BioMed research international |
| container_volume | 2021 |
| creator | Zhang, Jiayao Wang, Xiaoyu Li, Guangbing He, Jingyi Lu, Ziwen Yang, Yang Jiang, Yong Jiang, Liyong Li, Feiyu Liu, Jun |
| description | Purpose. This study is aimed at investigating the expression, underlying biological function, and clinical significance of coatomer protein complex subunit beta 2 (COPB2) in hepatocellular carcinoma (HCC). Methods. HCC-related data were extracted from The Cancer Genome Atlas (TCGA) database, International Cancer Genome Consortium (ICGC) database, and Gene Expression Omnibus (GEO) database. A logistic regression module was applied to analyze the relationship between the expression of COPB2 and clinicopathologic characteristics. The Cox proportional hazard regression model and Kaplan–Meier method were used for survival analysis. Gene set enrichment analysis (GSEA) was used to annotate the underlying biological functions. Loss-of-function experiments were conducted to determine the underlying mechanisms. Results. COPB2 was overexpressed in HCC, and high expression of COPB2 was significantly correlated with higher alpha fetoprotein (AFP) (odds ratio OR=1.616, >20 vs. ≤20, p |
| doi_str_mv | 10.1155/2021/6648078 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8007342</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A684259803</galeid><sourcerecordid>A684259803</sourcerecordid><originalsourceid>FETCH-LOGICAL-c504t-ba7c702da25d89615b5fd3ea2f78febab519b31d484d01db09e70c7e625ceed63</originalsourceid><addsrcrecordid>eNp9kc1rFDEYh4MottTePMuAF8GuzXcyHoTtoFYotod6DpnkzW7q7KRNZiv-98266_pxaC4J5OF5P34IvST4HSFCnFJMyamUXGOln6BDygifScLJ0_2bsQN0XMoNrkcTiVv5HB0wpinXih-irru8OqPvm3nzNd3D0FzltBhTmaJrzmJa2fwdcnO9tFMzDwHcVH4RGUqJaWxSaM677gV6FuxQ4Hh3H6Fvnz5ed-ezi8vPX7r5xcwJzKdZb5VTmHpLhdetJKIXwTOwNCgdoLe9IG3PiOeae0x8j1tQ2CmQVDgAL9kR-rD13q77FXgH45TtYG5zrH3-NMlG8-_PGJdmke6NxlgxTqvgzU6Q090aymRWsTgYBjtCWhdDRV0PFkqRir7-D71J6zzW8TaUplJQLv9QCzuAiWNIta7bSM1ctrIVtSh-nNKcilZjVqmTLeVyKiVD2A9GsNmEbTZhm13YFX_19zL28O9oK_B2Cyzj6O2P-LjuAfS_rTA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2508265246</pqid></control><display><type>article</type><title>COPB2: A Novel Prognostic Biomarker That Affects Progression of HCC</title><source>MEDLINE</source><source>PubMed Central Open Access</source><source>Wiley Online Library (Open Access Collection)</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Zhang, Jiayao ; Wang, Xiaoyu ; Li, Guangbing ; He, Jingyi ; Lu, Ziwen ; Yang, Yang ; Jiang, Yong ; Jiang, Liyong ; Li, Feiyu ; Liu, Jun</creator><contributor>Tao, Junyan ; Junyan Tao</contributor><creatorcontrib>Zhang, Jiayao ; Wang, Xiaoyu ; Li, Guangbing ; He, Jingyi ; Lu, Ziwen ; Yang, Yang ; Jiang, Yong ; Jiang, Liyong ; Li, Feiyu ; Liu, Jun ; Tao, Junyan ; Junyan Tao</creatorcontrib><description><![CDATA[Purpose. This study is aimed at investigating the expression, underlying biological function, and clinical significance of coatomer protein complex subunit beta 2 (COPB2) in hepatocellular carcinoma (HCC). Methods. HCC-related data were extracted from The Cancer Genome Atlas (TCGA) database, International Cancer Genome Consortium (ICGC) database, and Gene Expression Omnibus (GEO) database. A logistic regression module was applied to analyze the relationship between the expression of COPB2 and clinicopathologic characteristics. The Cox proportional hazard regression model and Kaplan–Meier method were used for survival analysis. Gene set enrichment analysis (GSEA) was used to annotate the underlying biological functions. Loss-of-function experiments were conducted to determine the underlying mechanisms. Results. COPB2 was overexpressed in HCC, and high expression of COPB2 was significantly correlated with higher alpha fetoprotein (AFP) (odds ratio OR=1.616, >20 vs. ≤20, p<0.05), stage (OR=1.744, III vs. I, p<0.05), and grade (OR=1.746, G4+G3 vs. G2+G1, p<0.05). Kaplan–Meier survival analysis showed that HCC patients with high COPB2 expression had a worse prognosis than those with low COPB2 expression (p<0.0001 for TCGA cohort, p<0.05 for ICGC cohort). The univariate Cox (hazard ratio HR=1.068, p<0.0001) and multivariate Cox (HR=2.011, p<0.05) regression analyses suggested that COPB2 was an independent risk factor. GSEA showed that mTOR and other tumor-related signaling pathways were differentially enriched in the high COPB2 expression phenotype. Silencing of COPB2 inhibited the proliferation, migration, and invasion abilities by suppressing epithelial-mesenchymal transition and mTOR signaling. Conclusion. COPB2 is a novel prognostic biomarker and a promising therapeutic target for HCC.]]></description><identifier>ISSN: 2314-6133</identifier><identifier>EISSN: 2314-6141</identifier><identifier>DOI: 10.1155/2021/6648078</identifier><identifier>PMID: 33824874</identifier><language>eng</language><publisher>United States: Hindawi</publisher><subject>Analysis ; Biomarkers ; Biomarkers, Tumor - genetics ; Biomarkers, Tumor - metabolism ; Biomedical research ; Cancer ; Carcinoma, Hepatocellular - genetics ; Carcinoma, Hepatocellular - metabolism ; Carcinoma, Hepatocellular - mortality ; Carcinoma, Hepatocellular - pathology ; Cell cycle ; Cell Line, Tumor ; Coatomer Protein - genetics ; Coatomer Protein - metabolism ; Consortia ; Development and progression ; Diagnosis ; Disease Progression ; Disease-Free Survival ; Female ; Gene expression ; Gene set enrichment analysis ; Genetic aspects ; Genetic markers ; Genomes ; Genomics ; Hepatocellular carcinoma ; Hepatoma ; Humans ; Identification and classification ; Liver cancer ; Liver Neoplasms - genetics ; Liver Neoplasms - metabolism ; Liver Neoplasms - mortality ; Liver Neoplasms - pathology ; Male ; Medical prognosis ; Mesenchyme ; Metastasis ; Methods ; Neoplasm Proteins - genetics ; Neoplasm Proteins - metabolism ; Pathogenesis ; Phenotypes ; Physiological aspects ; Polyclonal antibodies ; Properties ; Proteins ; Regression analysis ; Regression models ; Risk analysis ; Risk factors ; Signaling ; Survival ; Survival analysis ; Survival Rate ; Therapeutic targets ; TOR protein ; Tumors ; Wound healing</subject><ispartof>BioMed research international, 2021, Vol.2021, p.6648078-14</ispartof><rights>Copyright © 2021 Jiayao Zhang et al.</rights><rights>COPYRIGHT 2021 John Wiley & Sons, Inc.</rights><rights>Copyright © 2021 Jiayao Zhang et al. This is an open access article distributed under the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. https://creativecommons.org/licenses/by/4.0</rights><rights>Copyright © 2021 Jiayao Zhang et al. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c504t-ba7c702da25d89615b5fd3ea2f78febab519b31d484d01db09e70c7e625ceed63</citedby><cites>FETCH-LOGICAL-c504t-ba7c702da25d89615b5fd3ea2f78febab519b31d484d01db09e70c7e625ceed63</cites><orcidid>0000-0002-6486-724X ; 0000-0003-4707-7286</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8007342/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8007342/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,4024,27923,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33824874$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Tao, Junyan</contributor><contributor>Junyan Tao</contributor><creatorcontrib>Zhang, Jiayao</creatorcontrib><creatorcontrib>Wang, Xiaoyu</creatorcontrib><creatorcontrib>Li, Guangbing</creatorcontrib><creatorcontrib>He, Jingyi</creatorcontrib><creatorcontrib>Lu, Ziwen</creatorcontrib><creatorcontrib>Yang, Yang</creatorcontrib><creatorcontrib>Jiang, Yong</creatorcontrib><creatorcontrib>Jiang, Liyong</creatorcontrib><creatorcontrib>Li, Feiyu</creatorcontrib><creatorcontrib>Liu, Jun</creatorcontrib><title>COPB2: A Novel Prognostic Biomarker That Affects Progression of HCC</title><title>BioMed research international</title><addtitle>Biomed Res Int</addtitle><description><![CDATA[Purpose. This study is aimed at investigating the expression, underlying biological function, and clinical significance of coatomer protein complex subunit beta 2 (COPB2) in hepatocellular carcinoma (HCC). Methods. HCC-related data were extracted from The Cancer Genome Atlas (TCGA) database, International Cancer Genome Consortium (ICGC) database, and Gene Expression Omnibus (GEO) database. A logistic regression module was applied to analyze the relationship between the expression of COPB2 and clinicopathologic characteristics. The Cox proportional hazard regression model and Kaplan–Meier method were used for survival analysis. Gene set enrichment analysis (GSEA) was used to annotate the underlying biological functions. Loss-of-function experiments were conducted to determine the underlying mechanisms. Results. COPB2 was overexpressed in HCC, and high expression of COPB2 was significantly correlated with higher alpha fetoprotein (AFP) (odds ratio OR=1.616, >20 vs. ≤20, p<0.05), stage (OR=1.744, III vs. I, p<0.05), and grade (OR=1.746, G4+G3 vs. G2+G1, p<0.05). Kaplan–Meier survival analysis showed that HCC patients with high COPB2 expression had a worse prognosis than those with low COPB2 expression (p<0.0001 for TCGA cohort, p<0.05 for ICGC cohort). The univariate Cox (hazard ratio HR=1.068, p<0.0001) and multivariate Cox (HR=2.011, p<0.05) regression analyses suggested that COPB2 was an independent risk factor. GSEA showed that mTOR and other tumor-related signaling pathways were differentially enriched in the high COPB2 expression phenotype. Silencing of COPB2 inhibited the proliferation, migration, and invasion abilities by suppressing epithelial-mesenchymal transition and mTOR signaling. Conclusion. COPB2 is a novel prognostic biomarker and a promising therapeutic target for HCC.]]></description><subject>Analysis</subject><subject>Biomarkers</subject><subject>Biomarkers, Tumor - genetics</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Biomedical research</subject><subject>Cancer</subject><subject>Carcinoma, Hepatocellular - genetics</subject><subject>Carcinoma, Hepatocellular - metabolism</subject><subject>Carcinoma, Hepatocellular - mortality</subject><subject>Carcinoma, Hepatocellular - pathology</subject><subject>Cell cycle</subject><subject>Cell Line, Tumor</subject><subject>Coatomer Protein - genetics</subject><subject>Coatomer Protein - metabolism</subject><subject>Consortia</subject><subject>Development and progression</subject><subject>Diagnosis</subject><subject>Disease Progression</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Gene expression</subject><subject>Gene set enrichment analysis</subject><subject>Genetic aspects</subject><subject>Genetic markers</subject><subject>Genomes</subject><subject>Genomics</subject><subject>Hepatocellular carcinoma</subject><subject>Hepatoma</subject><subject>Humans</subject><subject>Identification and classification</subject><subject>Liver cancer</subject><subject>Liver Neoplasms - genetics</subject><subject>Liver Neoplasms - metabolism</subject><subject>Liver Neoplasms - mortality</subject><subject>Liver Neoplasms - pathology</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Mesenchyme</subject><subject>Metastasis</subject><subject>Methods</subject><subject>Neoplasm Proteins - genetics</subject><subject>Neoplasm Proteins - metabolism</subject><subject>Pathogenesis</subject><subject>Phenotypes</subject><subject>Physiological aspects</subject><subject>Polyclonal antibodies</subject><subject>Properties</subject><subject>Proteins</subject><subject>Regression analysis</subject><subject>Regression models</subject><subject>Risk analysis</subject><subject>Risk factors</subject><subject>Signaling</subject><subject>Survival</subject><subject>Survival analysis</subject><subject>Survival Rate</subject><subject>Therapeutic targets</subject><subject>TOR protein</subject><subject>Tumors</subject><subject>Wound healing</subject><issn>2314-6133</issn><issn>2314-6141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>RHX</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kc1rFDEYh4MottTePMuAF8GuzXcyHoTtoFYotod6DpnkzW7q7KRNZiv-98266_pxaC4J5OF5P34IvST4HSFCnFJMyamUXGOln6BDygifScLJ0_2bsQN0XMoNrkcTiVv5HB0wpinXih-irru8OqPvm3nzNd3D0FzltBhTmaJrzmJa2fwdcnO9tFMzDwHcVH4RGUqJaWxSaM677gV6FuxQ4Hh3H6Fvnz5ed-ezi8vPX7r5xcwJzKdZb5VTmHpLhdetJKIXwTOwNCgdoLe9IG3PiOeae0x8j1tQ2CmQVDgAL9kR-rD13q77FXgH45TtYG5zrH3-NMlG8-_PGJdmke6NxlgxTqvgzU6Q090aymRWsTgYBjtCWhdDRV0PFkqRir7-D71J6zzW8TaUplJQLv9QCzuAiWNIta7bSM1ctrIVtSh-nNKcilZjVqmTLeVyKiVD2A9GsNmEbTZhm13YFX_19zL28O9oK_B2Cyzj6O2P-LjuAfS_rTA</recordid><startdate>2021</startdate><enddate>2021</enddate><creator>Zhang, Jiayao</creator><creator>Wang, Xiaoyu</creator><creator>Li, Guangbing</creator><creator>He, Jingyi</creator><creator>Lu, Ziwen</creator><creator>Yang, Yang</creator><creator>Jiang, Yong</creator><creator>Jiang, Liyong</creator><creator>Li, Feiyu</creator><creator>Liu, Jun</creator><general>Hindawi</general><general>John Wiley & Sons, Inc</general><general>Hindawi Limited</general><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7QO</scope><scope>7T7</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>CWDGH</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-6486-724X</orcidid><orcidid>https://orcid.org/0000-0003-4707-7286</orcidid></search><sort><creationdate>2021</creationdate><title>COPB2: A Novel Prognostic Biomarker That Affects Progression of HCC</title><author>Zhang, Jiayao ; Wang, Xiaoyu ; Li, Guangbing ; He, Jingyi ; Lu, Ziwen ; Yang, Yang ; Jiang, Yong ; Jiang, Liyong ; Li, Feiyu ; Liu, Jun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c504t-ba7c702da25d89615b5fd3ea2f78febab519b31d484d01db09e70c7e625ceed63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Analysis</topic><topic>Biomarkers</topic><topic>Biomarkers, Tumor - genetics</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Biomedical research</topic><topic>Cancer</topic><topic>Carcinoma, Hepatocellular - genetics</topic><topic>Carcinoma, Hepatocellular - metabolism</topic><topic>Carcinoma, Hepatocellular - mortality</topic><topic>Carcinoma, Hepatocellular - pathology</topic><topic>Cell cycle</topic><topic>Cell Line, Tumor</topic><topic>Coatomer Protein - genetics</topic><topic>Coatomer Protein - metabolism</topic><topic>Consortia</topic><topic>Development and progression</topic><topic>Diagnosis</topic><topic>Disease Progression</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Gene expression</topic><topic>Gene set enrichment analysis</topic><topic>Genetic aspects</topic><topic>Genetic markers</topic><topic>Genomes</topic><topic>Genomics</topic><topic>Hepatocellular carcinoma</topic><topic>Hepatoma</topic><topic>Humans</topic><topic>Identification and classification</topic><topic>Liver cancer</topic><topic>Liver Neoplasms - genetics</topic><topic>Liver Neoplasms - metabolism</topic><topic>Liver Neoplasms - mortality</topic><topic>Liver Neoplasms - pathology</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Mesenchyme</topic><topic>Metastasis</topic><topic>Methods</topic><topic>Neoplasm Proteins - genetics</topic><topic>Neoplasm Proteins - metabolism</topic><topic>Pathogenesis</topic><topic>Phenotypes</topic><topic>Physiological aspects</topic><topic>Polyclonal antibodies</topic><topic>Properties</topic><topic>Proteins</topic><topic>Regression analysis</topic><topic>Regression models</topic><topic>Risk analysis</topic><topic>Risk factors</topic><topic>Signaling</topic><topic>Survival</topic><topic>Survival analysis</topic><topic>Survival Rate</topic><topic>Therapeutic targets</topic><topic>TOR protein</topic><topic>Tumors</topic><topic>Wound healing</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhang, Jiayao</creatorcontrib><creatorcontrib>Wang, Xiaoyu</creatorcontrib><creatorcontrib>Li, Guangbing</creatorcontrib><creatorcontrib>He, Jingyi</creatorcontrib><creatorcontrib>Lu, Ziwen</creatorcontrib><creatorcontrib>Yang, Yang</creatorcontrib><creatorcontrib>Jiang, Yong</creatorcontrib><creatorcontrib>Jiang, Liyong</creatorcontrib><creatorcontrib>Li, Feiyu</creatorcontrib><creatorcontrib>Liu, Jun</creatorcontrib><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Middle East & Africa Database</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BioMed research international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, Jiayao</au><au>Wang, Xiaoyu</au><au>Li, Guangbing</au><au>He, Jingyi</au><au>Lu, Ziwen</au><au>Yang, Yang</au><au>Jiang, Yong</au><au>Jiang, Liyong</au><au>Li, Feiyu</au><au>Liu, Jun</au><au>Tao, Junyan</au><au>Junyan Tao</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>COPB2: A Novel Prognostic Biomarker That Affects Progression of HCC</atitle><jtitle>BioMed research international</jtitle><addtitle>Biomed Res Int</addtitle><date>2021</date><risdate>2021</risdate><volume>2021</volume><spage>6648078</spage><epage>14</epage><pages>6648078-14</pages><issn>2314-6133</issn><eissn>2314-6141</eissn><abstract><![CDATA[Purpose. This study is aimed at investigating the expression, underlying biological function, and clinical significance of coatomer protein complex subunit beta 2 (COPB2) in hepatocellular carcinoma (HCC). Methods. HCC-related data were extracted from The Cancer Genome Atlas (TCGA) database, International Cancer Genome Consortium (ICGC) database, and Gene Expression Omnibus (GEO) database. A logistic regression module was applied to analyze the relationship between the expression of COPB2 and clinicopathologic characteristics. The Cox proportional hazard regression model and Kaplan–Meier method were used for survival analysis. Gene set enrichment analysis (GSEA) was used to annotate the underlying biological functions. Loss-of-function experiments were conducted to determine the underlying mechanisms. Results. COPB2 was overexpressed in HCC, and high expression of COPB2 was significantly correlated with higher alpha fetoprotein (AFP) (odds ratio OR=1.616, >20 vs. ≤20, p<0.05), stage (OR=1.744, III vs. I, p<0.05), and grade (OR=1.746, G4+G3 vs. G2+G1, p<0.05). Kaplan–Meier survival analysis showed that HCC patients with high COPB2 expression had a worse prognosis than those with low COPB2 expression (p<0.0001 for TCGA cohort, p<0.05 for ICGC cohort). The univariate Cox (hazard ratio HR=1.068, p<0.0001) and multivariate Cox (HR=2.011, p<0.05) regression analyses suggested that COPB2 was an independent risk factor. GSEA showed that mTOR and other tumor-related signaling pathways were differentially enriched in the high COPB2 expression phenotype. Silencing of COPB2 inhibited the proliferation, migration, and invasion abilities by suppressing epithelial-mesenchymal transition and mTOR signaling. Conclusion. COPB2 is a novel prognostic biomarker and a promising therapeutic target for HCC.]]></abstract><cop>United States</cop><pub>Hindawi</pub><pmid>33824874</pmid><doi>10.1155/2021/6648078</doi><tpages>14</tpages><orcidid>https://orcid.org/0000-0002-6486-724X</orcidid><orcidid>https://orcid.org/0000-0003-4707-7286</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2314-6133 |
| ispartof | BioMed research international, 2021, Vol.2021, p.6648078-14 |
| issn | 2314-6133 2314-6141 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8007342 |
| source | MEDLINE; PubMed Central Open Access; Wiley Online Library (Open Access Collection); PubMed Central; Alma/SFX Local Collection |
| subjects | Analysis Biomarkers Biomarkers, Tumor - genetics Biomarkers, Tumor - metabolism Biomedical research Cancer Carcinoma, Hepatocellular - genetics Carcinoma, Hepatocellular - metabolism Carcinoma, Hepatocellular - mortality Carcinoma, Hepatocellular - pathology Cell cycle Cell Line, Tumor Coatomer Protein - genetics Coatomer Protein - metabolism Consortia Development and progression Diagnosis Disease Progression Disease-Free Survival Female Gene expression Gene set enrichment analysis Genetic aspects Genetic markers Genomes Genomics Hepatocellular carcinoma Hepatoma Humans Identification and classification Liver cancer Liver Neoplasms - genetics Liver Neoplasms - metabolism Liver Neoplasms - mortality Liver Neoplasms - pathology Male Medical prognosis Mesenchyme Metastasis Methods Neoplasm Proteins - genetics Neoplasm Proteins - metabolism Pathogenesis Phenotypes Physiological aspects Polyclonal antibodies Properties Proteins Regression analysis Regression models Risk analysis Risk factors Signaling Survival Survival analysis Survival Rate Therapeutic targets TOR protein Tumors Wound healing |
| title | COPB2: A Novel Prognostic Biomarker That Affects Progression of HCC |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T03%3A04%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=COPB2:%20A%20Novel%20Prognostic%20Biomarker%20That%20Affects%20Progression%20of%20HCC&rft.jtitle=BioMed%20research%20international&rft.au=Zhang,%20Jiayao&rft.date=2021&rft.volume=2021&rft.spage=6648078&rft.epage=14&rft.pages=6648078-14&rft.issn=2314-6133&rft.eissn=2314-6141&rft_id=info:doi/10.1155/2021/6648078&rft_dat=%3Cgale_pubme%3EA684259803%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2508265246&rft_id=info:pmid/33824874&rft_galeid=A684259803&rfr_iscdi=true |